Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.
Batch number on every vial
Published Certificates of Analysis
Purity verified by third-party testing
Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.
Semaglutide (50 mg) is a synthetic, long-acting glucagon-like peptide-1 (GLP-1) analogue designed to mimic natural GLP-1 activity with extended stability. It consists of a 31-amino-acid backbone, modified at key positions, and a C18 fatty diacid side chain for improved albumin binding and reduced enzymatic degradation. This enhances its prolonged activity in experimental models.
Semaglutide’s molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of 4113.6 g/mol, and shares 94% sequence homology with native GLP-1, making it ideal for peptide-based metabolic research.
The peptide is supplied as a high-purity lyophilized powder in vials for batch preparation and repeated experimental use. Research focuses on metabolic regulation, energy balance, and glucose homeostasis.
For laboratory research use only.
Semaglutide (50 mg) is being investigated for its role in metabolic regulation, particularly in glucose balance, appetite, and energy expenditure. It has been studied in models for its effects on pancreatic function, insulin signaling, and hepatic glucose output, with relevance to metabolic disorders like type 2 diabetes and obesity.
Research also explores Semaglutide’s influence on central appetite pathways and gastrointestinal processes, including gastric emptying. These mechanisms are examined in both animal models and clinical trials to understand the role of peptide signaling in food intake and weight regulation.
Beyond metabolic endpoints, studies have explored its role in cardiovascular health, renal function, and liver fat metabolism. Ongoing research also examines its effects on inflammation and neural signaling, particularly in conditions associated with metabolic dysfunction.
These applications are still investigational. This peptide is a research tool and is not intended for clinical or therapeutic use.
Pharmacokinetic analyses show Semaglutide’s half-life ranges from 145 to 170 hours, supporting once-weekly dosing in experimental designs.
In clinical research, subcutaneous doses ranging from 0.25 mg to 2.4 mg per week have shown dose-dependent changes in metabolic parameters such as fasting glucose and HbA1c. Oral formulations, with daily doses up to 50 mg, have been studied in obesity trials, providing data on absorption, bioavailability, and systemic exposure.
Semaglutide has been associated with significant changes in body weight, appetite regulation, and glycemic markers in a dose-dependent manner. However, these outcomes should be interpreted within the context of clinical research, not generalized use.
In preclinical and clinical study cohorts, gastrointestinal (GI) events such as nausea, vomiting, and diarrhea were among the most frequently documented. Delayed gastric emptying and gallbladder-related findings have also been reported. Rare events such as pancreatitis or visual disturbances have been noted, highlighting the need for safety considerations in study design and monitoring in research settings.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
Subscribe for exclusive offers and updates on new arrivals